Metastatic NSCLC with ROS1 Rearrangement and Multiple Acquired Resistance Mechanisms to Tyrosine Kinase Inhibitor Therapy: Chasing the Target

shaverdashvili full page
Download (1.32 MB)
General
Metastatic NSCLC with ROS1 Rearrangement and Multiple Acquired Resistance Mechanisms to Tyrosine Kinase Inhibitor Therapy: Chasing the Target

Khvaramze Shaverdashvili, MD
Timothy F. Burns, MD, PhD
United States